Agilent Technologies Inc. (NYSE: A) announces it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. Both BIOVECTRA and Agilent are fully integrated CDMOs with state-of-the-art facilities that follow current Good Manufacturing Practices (cGMP), a high standard for methods, facilities, and controls used in manufacturing, processing, and packaging of active pharmaceutical ingredients.
Read the full article: Agilent to Acquire North American CDMO BIOVECTRA //
Source: https://www.businesswire.com/news/home/20240722078870/en/Agilent-to-Acquire-North-American-CDMO-BIOVECTRA